Statins inhibit HIV-1 infection by down-regulating Rho activity

Area of Science:

• Virology
• Cell Biology
• Pharmacology

Background:

• Human immunodeficiency virus (HIV)-1 infectivity depends on actin-dependent receptor clustering, potentially involving Rho guanosine triphosphatase (GTPase) activation.
• Statins, cholesterol-lowering drugs, inhibit Rho GTPase activity by blocking prenylation via 3-hydroxy-3-methylglutaryl coenzyme A reductase.
• Rho GTPase signaling is implicated in viral entry and replication.

Purpose of the Study:

• To investigate the direct anti-HIV-1 effects of statins.
• To determine the role of Rho GTPase pathway in HIV-1 infectivity.
• To assess the therapeutic potential of statins in HIV-1 infection.

Main Methods:

• Infection models and HIV-1-infected patients were treated with statins.
• Viral load and CD4+ cell counts were monitored.
• Viral entry and exit assays were performed in statin-treated cells.
• Effects of l-mevalonate, geranylgeranylpyrophosphate, and cholesterol were assessed.
• Geranylgeranyl and farnesyl transferase inhibitors were used.
• Rho-A activation and HIV-1 envelope fusion were analyzed.

Main Results:

• Statins significantly decreased viral load and increased CD4+ cell counts in both acute and chronic HIV-1 infection models and patients.
• Statin treatment reduced viral entry and exit, an effect reversed by l-mevalonate or geranylgeranylpyrophosphate.
• Geranylgeranyl transferase inhibition, but not farnesyl transferase inhibition, specifically blocked HIV-1 entry.
• Statins inhibited Rho-A activation induced by HIV-1 binding.
• Expression of a dominant-negative Rho mutant reduced HIV-1 envelope fusion and infection rates.

Conclusions:

• Statins exert direct anti-HIV-1 effects by targeting the Rho GTPase pathway.
• Inhibition of Rho GTPase prenylation by statins disrupts HIV-1 infectivity.
• Statins represent a potential therapeutic strategy for HIV-1 infection by modulating host cell pathways.